<p><strong>Pediatric Use</strong>: The safety and efficacy of Dasatinib in patients less than 18 years of age have not been established.<br />
<br />
<strong>Geriatric Use</strong>: No differences in confirmed Complete Cytogenetic Response (cCCyR) and&nbsp;MMR&nbsp;were observed between older and younger patients. Of the 2712 patients in clinical studies of Dasatinib, 617 (23%) were 65 years of age and older, and 123 (5%) were 75 years of age and older. While the safety profile of Dasatinib in the geriatric population was similar to that in the younger population, patients aged 65 years and older are more likely to experience the commonly reported adverse reactions of fatigue, pleural effusion, diarrhea, dyspnea, cough, lower gastrointestinal hemorrhage, and appetite disturbance, and more likely to experience the less frequently reported adverse reactions of abdominal&nbsp;distention, dizziness,&nbsp;pericardial effusion, congestive heart failure,&nbsp;hypertension,&nbsp;pulmonary edema, and weight decrease, and should be monitored closely.<br />
<br />
<strong>Hepatic Impairment</strong>: No dosage adjustment is necessary in patients with hepatic impairment. Caution is recommended when administering Dasatinib to patients with hepatic impairment.<br />
<br />
<strong>Renal Impairment</strong>: There are currently no clinical studies with Dasatinib in patients with impaired renal function. Less than 4% of dasatinib and its metabolites are excreted via the kidney.</p>